Another phase I/II trial, TOPACIO, showed an ORR of 21% in 55 metastatic triple-negative breast cancer (TNBC) patients treated by the combination of niraparib (PARP inhibitor) and pembrolizumab and the ORR was higher in BRCA1/2-mutant patients than in BRCA1/2-wt (wt: wide type) patients (47% vs. 11%) [84]. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.